27 Jun, 2017

Somahlution Announces Medical University of Vienna as First Austrian Site to Participate in DuraGraft Registry

27 Jun, 2017

JUPITER, FL May. 5, 2017 — Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical...

Read more
27 Jun, 2017

Somahlution Announces DuraGraft Registry Initiation at Leading Cardiac Surgery Hospitals in Germany

27 Jun, 2017

JUPITER, Fl.- Somahlution announces the first German patient enrolled in its DuraGraft® European Registry clinical trial. The patient was treated by Dr. Prof. Herbert Vetter, Chief Physician at Helios Hospital Wuppertal....

Read more
07 Apr, 2017

Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery

07 Apr, 2017

Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery First-in-class intraoperative vascular graft treatment shown to reduce the risk of...

Read more
28 Feb, 2017

Somahlution announced enrollment of the first subject in their DuraGraft® CABG European Registry

28 Feb, 2017

JUPITER, Fla., Jan. 4, 2017 — Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications,...

Read more
28 Feb, 2017

Somahlution Announces Multiple Site Initiation and Patient Enrollment in Spain for European DuraGraft ®Registry.

28 Feb, 2017

Somahlution Announces Multiple Site Initiation and Patient Enrollment in Spain for European DuraGraft Registry.

Read more